Latest Healthcare Sector News

Lumos Diagnostics has voluntarily suspended its ASX trading pending a market announcement about strategic agreements, signaling potential shifts in its business trajectory.

Pharmx Technologies has resumed trading on the ASX following the renewal of its pivotal National Diabetes Services Scheme agreement, signaling stability for the healthcare tech firm.

Echo IQ has secured a pivotal reseller agreement with US-based SARC MedIQ, unlocking access to over 300 healthcare facilities and accelerating adoption of its AI-driven EchoSolv AS technology across the American cardiology landscape.

Universal Biosensors will lift its trading suspension following the announcement of a non-binding term sheet for a senior secured loan facility, signaling a potential boost to its financial position.

Proteomics International has achieved a major milestone with the first worldwide patent granted in Japan for its PromarkerEndo blood test, designed to diagnose endometriosis early and accurately.

Microba Life Sciences invites eligible shareholders to participate in a $2 million Share Purchase Plan at $0.09 per share, matching recent institutional pricing and including free attaching options. The capital raise aims to accelerate clinical adoption and push the company towards regional break-even.

Epsilon Healthcare and its subsidiaries have officially exited voluntary administration and Deeds of Company Arrangement, marking a pivotal recovery milestone supported by significant personal commitments from the new board. The company now shifts focus to strategic growth and rebuilding trust.

ParagonCare appoints Carmen Riley as CEO effective July 1, 2025, with a planned transition period under outgoing CEO David Collins to complete integration and pursue M&A opportunities.

BlinkLab Limited has responded to an ASX query regarding recent unusual trading activity, confirming no undisclosed material information exists and highlighting pending ADHD diagnostic results expected later this year.

Microba Life Sciences Limited has had its trading suspension lifted following a capital raising announcement, signaling renewed market activity for the healthcare company.

Universal Biosensors has requested a voluntary suspension of its shares on the ASX, pending details of a proposed capital raising. The suspension is expected to last until the end of June or until the announcement is made.

Hydralyte USA reported its strongest monthly sales in May 2025, alongside continued improvement in EBITDA losses, signaling steady progress toward profitability.